Agios Pharmaceuticals Stock Forecast, Price & News

-1.76 (-2.96 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume561,805 shs
Average Volume695,118 shs
Market Capitalization$3.56 billion
P/E Ratio2.53
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Agios Pharmaceuticals logo

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.26 out of 5 stars

Medical Sector

910th out of 2,096 stocks

Pharmaceutical Preparations Industry

442nd out of 830 stocks

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

Is Agios Pharmaceuticals a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Agios Pharmaceuticals stock.
View analyst ratings for Agios Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Agios Pharmaceuticals?

Wall Street analysts have given Agios Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Agios Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Agios Pharmaceuticals

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings results on Wednesday, April, 28th. The biopharmaceutical company reported $26.95 earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.23) by $28.18. Agios Pharmaceuticals had a negative net margin of 161.11% and a negative trailing twelve-month return on equity of 40.48%.
View Agios Pharmaceuticals' earnings history

How has Agios Pharmaceuticals' stock price been impacted by Coronavirus?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AGIO shares have increased by 41.3% and is now trading at $57.74.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AGIO?

12 brokers have issued 12-month price targets for Agios Pharmaceuticals' stock. Their forecasts range from $50.00 to $88.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $67.67 in the next year. This suggests a possible upside of 17.2% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Dr. Jacqualyn A. Fouse, CEO & Director (Age 60, Pay $1.27M)
  • Mr. Jonathan Biller J.D., CFO and Head of Legal & Corp. Affairs (Age 57, Pay $769.33k)
  • Dr. Bruce Car Ph.D., Chief Scientific Officer (Age 59, Pay $894.8k)
  • Dr. Christopher J. Bowden, Chief Medical Officer (Age 60, Pay $767.55k)
  • Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 72)
  • Dr. Tak Wah Mak, Co-Founder & Member of Scientific Advisory Board (Age 75)
  • Dr. Craig B. Thompson, Co-Founder & Chairman of Scientific Advisory Board (Age 68)
  • Dr. Shin-San Su Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 65)
  • Ms. Carman Alenson, Principal Accounting Officer and VP of Accounting, Treasury & Tax
  • Dr. Clive Patience, Exec. VP of Technical Operations (Age 57)

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals CEO Jackie Fouse on Jackie Fouse has an approval rating of 100% among Agios Pharmaceuticals' employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.69%), Bellevue Group AG (6.49%), Price T Rowe Associates Inc. MD (4.81%), Rock Springs Capital Management LP (4.13%), Suvretta Capital Management LLC (1.76%) and Woodline Partners LP (1.34%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, Darrin Miles, David P Schenkein and Jacqualyn A Fouse.
View institutional ownership trends for Agios Pharmaceuticals

Which institutional investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Capital International Investors, D. E. Shaw & Co. Inc., Point72 Asset Management L.P., PDT Partners LLC, Alliancebernstein L.P., Credit Suisse AG, and Russell Investments Group Ltd.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, and Darrin Miles.
View insider buying and selling activity for Agios Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Agios Pharmaceuticals stock?

AGIO stock was purchased by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Woodline Partners LP, Bellevue Group AG, Eagle Health Investments LP, BlackRock Inc., Morgan Stanley, Citigroup Inc., and HRT Financial LP. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $57.74.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals has a market capitalization of $3.56 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $-327,370,000.00 in net income (profit) each year or ($4.74) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

Agios Pharmaceuticals employs 562 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is

Where are Agios Pharmaceuticals' headquarters?

Agios Pharmaceuticals is headquartered at 88 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.